147 related articles for article (PubMed ID: 37125618)
1. Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted
Shahidi M; Abazari O; Dayati P; Reza JZ; Modarressi MH; Tofighi D; Haghiralsadat BF; Oroojalian F
Nanomedicine (Lond); 2023 Feb; 18(3):259-277. PubMed ID: 37125618
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
Zhang W; Xu W; Lan Y; He X; Liu K; Liang Y
Int J Nanomedicine; 2019; 14():5287-5301. PubMed ID: 31406460
[No Abstract] [Full Text] [Related]
3. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy.
Xia Y; Guo M; Xu T; Li Y; Wang C; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():1539-1552. PubMed ID: 29588583
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
Ganesh S; Iyer AK; Morrissey DV; Amiji MM
Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
[TBL] [Abstract][Full Text] [Related]
5. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
6. Development of hyaluronic acid-anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer.
Jain D; Yadav AK
Drug Deliv Transl Res; 2023 Jun; 13(6):1730-1744. PubMed ID: 36641487
[TBL] [Abstract][Full Text] [Related]
7. Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics.
Wang Z; Zhao S; Shi J; Meng F; Yuan J; Zhong Z
Acta Biomater; 2022 Jan; 138():443-452. PubMed ID: 34757229
[TBL] [Abstract][Full Text] [Related]
8. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
Zou J; Su S; Chen Z; Liang F; Zeng Y; Cen W; Zhang X; Xia Y; Huang D
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3456-3464. PubMed ID: 31469318
[TBL] [Abstract][Full Text] [Related]
10. Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer.
Liang Y; Wang Y; Wang L; Liang Z; Li D; Xu X; Chen Y; Yang X; Zhang H; Niu H
Bioact Mater; 2021 Feb; 6(2):433-446. PubMed ID: 32995671
[TBL] [Abstract][Full Text] [Related]
11. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
[TBL] [Abstract][Full Text] [Related]
12. Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.
Hou L; Song Z; Xu Z; Wu Y; Shi W
Int J Nanomedicine; 2020; 15():1397-1408. PubMed ID: 32184594
[TBL] [Abstract][Full Text] [Related]
13. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
14. A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells.
Yao H; Sun L; Li J; Zhou X; Li R; Shao R; Zhang Y; Li L
Int J Nanomedicine; 2020; 15():7013-7034. PubMed ID: 33061365
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-fabricated nanogold delivery of the inhibitor of apoptosis protein-2 siRNAs inhibits benzo[a]pyrene-induced oncogenic properties of lung cancer A549 cells.
Lin CM; Kao WC; Yeh CA; Chen HJ; Lin SZ; Hsieh HH; Sun WS; Chang CH; Hung HS
Nanotechnology; 2015 Mar; 26(10):105101. PubMed ID: 25693888
[TBL] [Abstract][Full Text] [Related]
16. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
17. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression.
Masjedi A; Ahmadi A; Atyabi F; Farhadi S; Irandoust M; Khazaei-Poul Y; Ghasemi Chaleshtari M; Edalati Fathabad M; Baghaei M; Haghnavaz N; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Sabz G; Hasanzadeh S; Jadidi-Niaragh F
Int J Biol Macromol; 2020 Apr; 149():487-500. PubMed ID: 32004600
[TBL] [Abstract][Full Text] [Related]
18. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
[TBL] [Abstract][Full Text] [Related]
19. Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery.
Lallana E; Rios de la Rosa JM; Tirella A; Pelliccia M; Gennari A; Stratford IJ; Puri S; Ashford M; Tirelli N
Mol Pharm; 2017 Jul; 14(7):2422-2436. PubMed ID: 28597662
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-coated chitosan nanoparticles as carrier for the enzyme/prodrug complex based on horseradish peroxidase/indole-3-acetic acid: Characterization and potential therapeutic for bladder cancer cells.
Pereira FM; Melo MN; Santos ÁKM; Oliveira KV; Diz FM; Ligabue RA; Morrone FB; Severino P; Fricks AT
Enzyme Microb Technol; 2021 Oct; 150():109889. PubMed ID: 34489042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
